<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India Limited has submitted a disclosure to BSE confirming that it does not qualify as a 'Large Corporate' under SEBI's framework for fund raising by issuance of debt securities (SEBI Circular dated October 19, 2023). As per Annexure A, the company has zero outstanding borrowings as on March 31, 2025, and no credit rating is applicable. Since it falls below the Large Corporate threshold, the company has filed a NIL disclosure. The filing was signed by Whole-Time Director & CFO Shilpa Joshi and Company Secretary Chandni Maru on April 23, 2025.
This is a routine annual compliance disclosure with no material impact on the stock or shareholders. It does, however, signal that Novartis India is essentially debt-free as of March 31, 2025, reflecting a strong, unleveraged balance sheet.